Bluebird Bio Stock Alpha and Beta Analysis
| BLUE Stock | USD 3.88 0.20 4.90% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Bluebird bio. It also helps investors analyze the systematic and unsystematic risks associated with investing in Bluebird Bio over a specified time horizon. Remember, high Bluebird Bio's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Bluebird Bio's market risk premium analysis include:
Beta 1.08 | Alpha 0.53 | Risk 16.85 | Sharpe Ratio 0.0078 | Expected Return 0.13 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Bluebird |
Bluebird Bio Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Bluebird Bio market risk premium is the additional return an investor will receive from holding Bluebird Bio long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Bluebird Bio. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Bluebird Bio's performance over market.| α | 0.53 | β | 1.08 |
Bluebird Bio expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Bluebird Bio's Buy-and-hold return. Our buy-and-hold chart shows how Bluebird Bio performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Bluebird Bio Market Price Analysis
Market price analysis indicators help investors to evaluate how Bluebird Bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Bluebird Bio shares will generate the highest return on investment. By understating and applying Bluebird Bio stock market price indicators, traders can identify Bluebird Bio position entry and exit signals to maximize returns.
Bluebird Bio Return and Market Media
The median price of Bluebird Bio for the period between Tue, Dec 3, 2024 and Mon, Mar 3, 2025 is 7.8 with a coefficient of variation of 21.75. The daily time series for the period is distributed with a sample standard deviation of 1.65, arithmetic mean of 7.58, and mean deviation of 1.09. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation Cell and Gene Therapy Access Model | 12/04/2024 |
2 | Disposition of 2824 shares by Colvin Richard A of Bluebird Bio at 0.4173 subject to Rule 16b-3 | 12/10/2024 |
3 | bluebird bio Now Covered by StockNews.com - MarketBeat | 12/19/2024 |
4 | Disposition of 140 shares by Andrew Obenshain of Bluebird Bio at 9.24 subject to Rule 16b-3 | 01/06/2025 |
5 | Disposition of 4526 shares by Krawtschuk Christopher of Bluebird Bio at 4.5155 subject to Rule 16b-3 | 01/10/2025 |
6 | LE RAPPORT BLUE SHIFT DARTHUR D. LITTLE EXPLORE LIMPACT DE LIA SUR LA TRANSFORMATION DE LA RECHERCHE, DU DVELOPPEMENT ET DE LINNOVATION. | 01/15/2025 |
7 | Disposition of tradable shares by Andrew Obenshain of Bluebird Bio at 7.3925 subject to Rule 16b-3 | 02/03/2025 |
8 | Car T Cell Therapy Market Projected To Witness Substantial Growth, 2025-2032 Pfizer, bluebird bio, Johnson Johnson | 02/06/2025 |
9 | Acquisition by Andrew Obenshain of 763 shares of Bluebird Bio subject to Rule 16b-3 | 02/10/2025 |
10 | Blue Point Brewing Announces 5th Annual Shakedown on Main Street Festival | 02/11/2025 |
11 | BLUE CROSS BLUE SHIELD OF MASSACHUSETTS ENHANCES DIABETES SUPPORT FOR MEMBERS | 02/19/2025 |
12 | Stocks Firmly Lower As Consumer Sentiment Weakens | 02/21/2025 |
13 | Biotech Stock Roundup BLUE Down on Update, News From GILD, TRDA | 02/26/2025 |
14 | Acquisition by Leiderman Elisabeth of 24900 shares of Bluebird Bio subject to Rule 16b-3 | 02/27/2025 |
15 | bluebird bio stock slides for second day on buyout news - MSN | 02/28/2025 |
About Bluebird Bio Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Bluebird or other stocks. Alpha measures the amount that position in Bluebird bio has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Graham Number | 13.81 | 8.77 | 7.89 | 7.5 | Receivables Turnover | 0.33 | 2.27 | 2.61 | 2.48 |
Bluebird Bio Upcoming Company Events
As portrayed in its financial statements, the presentation of Bluebird Bio's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bluebird Bio's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Bluebird Bio's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Bluebird Bio. Please utilize our Beneish M Score to check the likelihood of Bluebird Bio's management manipulating its earnings.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Bluebird Bio
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Bluebird Bio Backtesting, Bluebird Bio Valuation, Bluebird Bio Correlation, Bluebird Bio Hype Analysis, Bluebird Bio Volatility, Bluebird Bio History and analyze Bluebird Bio Performance. For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Bluebird Bio technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.